Glaukos (GKOS) Expected to Announce Quarterly Earnings on Wednesday

Glaukos (NYSE:GKOS) is expected to announce its Q1 2026 results after the market closes on Wednesday, April 29th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $136.8880 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 4:30 PM ET.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The business had revenue of $143.12 million during the quarter, compared to analyst estimates of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The company’s revenue was up 35.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.40) earnings per share. On average, analysts expect Glaukos to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $121.94 on Monday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69. Glaukos has a 52 week low of $73.16 and a 52 week high of $130.23. The firm has a market cap of $7.14 billion, a PE ratio of -37.40 and a beta of 0.78. The firm’s fifty day moving average is $113.09 and its 200-day moving average is $106.86.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GKOS. Stifel Nicolaus raised their target price on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Stephens upped their price target on Glaukos from $115.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, January 2nd. Wall Street Zen cut Glaukos from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Wells Fargo & Company raised their price objective on Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Finally, Needham & Company LLC lifted their price objective on Glaukos from $125.00 to $127.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $133.69.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Aimee S. Weisner sold 15,000 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $117.38, for a total value of $1,760,700.00. Following the completion of the sale, the director directly owned 18,806 shares in the company, valued at approximately $2,207,448.28. This trade represents a 44.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Alex R. Thurman sold 2,511 shares of Glaukos stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total transaction of $267,321.06. Following the completion of the sale, the chief financial officer directly owned 41,967 shares of the company’s stock, valued at approximately $4,467,806.82. This trade represents a 5.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 19,657 shares of company stock worth $2,250,060. 6.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its holdings in Glaukos by 10.4% in the third quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock worth $292,004,000 after acquiring an additional 336,266 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of Glaukos by 49.8% during the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock valued at $381,289,000 after acquiring an additional 1,123,140 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Glaukos by 183.4% during the fourth quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock worth $340,855,000 after purchasing an additional 1,953,578 shares during the period. State Street Corp lifted its holdings in shares of Glaukos by 0.9% in the 4th quarter. State Street Corp now owns 2,122,402 shares of the medical instruments supplier’s stock worth $239,640,000 after purchasing an additional 18,040 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Glaukos by 3.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock worth $206,503,000 after purchasing an additional 68,497 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.